78 T-Cell, MHC I, and tumor intrinsic gene signatures predict clinical benefit and resistance to tislelizumab monotherapy in pretreated PD-L1+ urothelial carcinoma
Ye, D., et al. 78 T-Cell, MHC I, and tumor intrinsic gene signatures predict clinical benefit and resistance to tislelizumab monotherapy in pretreated PD-L1+ urothelial carcinoma. Journal for Immunotherapy of Cancer 2020(8)S3: A1-A959- pre-print